High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients

OBJECTIVE: To evaluate B-cell- and T-cell-mediated immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases previously been treated with or under continuous treatment with B-cell-targeted therapies including rituximab (RTX) and belimumab (BEL). MAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabris, Martina, De Marchi, Ginevra, Domenis, Rossana, Caponnetto, Federica, Guella, Silvia, Dal Secco, Chiara, Cabas, Nicola, De Vita, Salvatore, Beltrami, Antonio Paolo, Curcio, Francesco, Quartuccio, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995326/
https://www.ncbi.nlm.nih.gov/pubmed/35427999
http://dx.doi.org/10.1016/j.jaut.2022.102827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995326/
https://www.ncbi.nlm.nih.gov/pubmed/35427999
http://dx.doi.org/10.1016/j.jaut.2022.102827

Ejemplares similares